Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-In-Human Study of ABD-3001 in R/R AML and High-Risk MDS
NCT05601726Phase 2Recruiting
- Sponsor
- Advanced BioDesign
- Start
- Nov 2022
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dimethyl ampal thiolester in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by Advanced BioDesign. Started Nov 2022; status: recruiting.
02
Drugs
dimethyl ampal thiolester
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT05601726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05601726.